𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Capecitabine (Xeloda™) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma

✍ Scribed by C Twelves; M Boyer; M Findlay; J Cassidy; C Weitzel; C Barker; B Osterwalder; C Jamieson; K Hieke

Book ID
117657144
Publisher
Elsevier Science
Year
2001
Tongue
English
Weight
138 KB
Volume
37
Category
Article
ISSN
0959-8049

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II trial of weekly high dose con
A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer
✍ Enrique Aranda; Andrés Cervantes; Javier Dorta; Esperanza Blanco; Carlos Fernánd 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 419 KB 👁 2 views

Background. In a previous Phase I1 trial, the authors showed that a weekly continuous infusion of 5-fluorouracil (5-FU) at a dose of 3.5 g/mz for 48 hours is an active treatment for advanced colorectal cancer. The overall response rate was 38.5%, and the median survival was 12 months. These data wer

A prospective, randomized phase III tria
A prospective, randomized phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma
✍ Cesar Blajman; L. Balbiani; J. Block; F. Coppola; R. Chacon; L. Fein; S. Bonicat 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB 👁 2 views

## Background: A prospective, multicenter, randomized, phase iii trial comparing the efficacy of combination chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide (fac) with a combination of vinorelbine and doxorubicin (na) in the treatment of patients with advanced breast carcinoma w